Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS)

被引：0
|
作者：
Coughlan, Anna [1 ]
Klijn, Sven L. [2 ]
Xiao, Hong [3 ]
White, Benjamin [4 ]
Litkiewicz, Michal [5 ]
Kadambi, Ananth [4 ]
Sichevaya, Alina
Hnoosh, Ahmed [6 ]
Miteva, Dimana [7 ]
Yucel, Aylin [3 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Bristol Myers Squibb, Lawrence, NJ USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Evidera, San Francisco, CA USA
[5] Evidera, London, England
[6] Evidera, London, England
[7] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
myelodysplastic syndromes; transfusion independence; burden of illness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-008
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [41] Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and L-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    Giagounidis, Aristoteles
    List, Alan
    Schlegelberger, Brigitte
    Fenaux, Pierre
    Shiansong, Jack
    Sugrue, Mary M.
    BLOOD, 2013, 122 (21)
  • [42] Luspatercept Versus Epoetin Alfa for Treatment (Tx) of Anemia in Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients (pts) Requiring RBC Transfusions (RBCT): Data from the Phase 3 COMMANDS Study
    Platzbecker, U.
    Della Porta, M. G.
    Santini, V.
    Zeidan, A. M.
    Fenaux, P.
    Komrokji, R. S.
    Shortt, J.
    Valcarcel, D.
    Jonasova, A.
    Dimicoli-Salazar, S.
    Tiong, I. S.
    Lin, C. -C.
    Li, J.
    Zhang, J.
    Giuseppi, A. C.
    Kreitz, S.
    Pozharskaya, V.
    Keeperman, K. L.
    Rose, S.
    Shetty, J. K.
    Hayati, S.
    Vodala, S.
    Degulys, A.
    Paolini, S.
    Cluzeau, T.
    Garcia-Manero, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 16 - 17
  • [43] Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study
    Platzbecker, Uwe
    Komrokji, Rami S.
    Fenaux, Pierre
    Zeidan, Amer M.
    Sekeres, Mikkael A.
    Savona, Michael Robert
    Madanat, Yazan F.
    Santini, Valeria
    Van Eygen, Koen
    Raza, Azra
    Germing, Ulrich
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Huang, Fei
    Feller, Faye
    Wan, Ying
    Ikin, Annat
    Sherman, Laurie
    BLOOD, 2022, 140 : 1106 - 1108
  • [44] Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).
    Garcia-Manero, Guillermo
    Platzbecker, Uwe
    Santini, Valeria
    Zeidan, Amer Methqal
    Fenaux, Pierre
    Komrokji, Rami S.
    Shortt, Jake
    Valcarcel, David
    Jonasova, Anna
    Dimicoli-Salazar, Sophie
    Tiong, Ing Soo
    Lin, Chien-Chin
    Li, Jiahui
    Kreitz, Sandra
    Pozharskaya, Veronika
    Shetty, Jeevan K.
    Degulys, Andrius
    Finelli, Carlo
    Cluzeau, Thomas
    Della Porta, Matteo Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] A Phase III Placebo-Controlled Trial of CC-486 in Patients With Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia Due to IPSS Lower-Risk Myelodysplastic Syndromes
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 9 - 10
  • [46] Luspatercept significantly reduces red blood cell transfusion burden, regardless of gene mutation frequency, spectrum, and prognostic significance, among patients with lower-risk myelodysplastic syndromes enrolled in the MEDALIST trial
    Mufti, G. J.
    Vyas, P.
    Garcia-Manero, G.
    Buckstein, R.
    Santini, V.
    Diez-Campelo, M.
    Finelli, C.
    Ilhan, O.
    Sekeres, M. A.
    Komrokji, R. S.
    Zeidan, A. M.
    Verma, A.
    Dunshee, R.
    Laadem, A.
    Linde, P. G.
    List, A. F.
    Fenaux, P.
    Platzbecker, U.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 149 - 150
  • [47] UPDATE ON SAFETY AND LONG-TERM OUTCOMES IN LENALIDOMIDE (LEN)-TREATED PATIENTS WITH RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND DEL(5Q)
    Hellstrom-Lindberg, E.
    Giagounidis, A.
    Selleslag, D.
    Mittelman, M.
    Muus, P.
    Benettaib, B.
    Fu, T.
    Fenaux, P.
    HAEMATOLOGICA, 2012, 97 : 358 - 359
  • [48] Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
    Santini, Valeria
    Zeidan, Amer M.
    Platzbecker, Uwe
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    Miteva, Dimana
    Yucel, Aylin
    Pozharskaya, Veronika
    Rose, Shelonitda
    Lai, Yinzhi
    Giuseppi, Ana Carolina
    Ferreiras, David Valcarcel
    Fenaux, Pierre
    Shortt, Jake
    Porta, Matteo Giovanni Della
    BLOOD, 2024, 144 : 1818 - 1820
  • [49] Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
    Oliva, Esther Natalie
    Platzbecker, Uwe
    Porta, Matteo Giovanni Della
    Garcia-Manero, Guillermo
    Santini, Ualeria
    Fenaux, Pierre
    Shortt, Jake
    Komrokji, Rami S.
    Pelligra, Christopher G.
    Guo, Shien
    Yucel, Aylin
    Glassberg, Mrudula B.
    Eliason, Laurie
    Hnoosh, Ahmed
    Miteva, Dimana
    Rose, Shelo
    Santiri, Valeria
    Kreitz, Sandra
    Sekeres, Mikkael A.
    Zeidan, Amer M.
    BLOOD, 2024, 144 : 3217 - 3218
  • [50] IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
    Zeidan, Amer Methqal
    Platzbecker, Uwe
    Santini, Valeria
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Savona, Michael R.
    Madanat, Yazan F.
    Diez-Campelo, Maria
    Valcarcel, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie Jill
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Wan, Ying
    Huang, Fei
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345